BRPI0407611A - agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo - Google Patents

agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo

Info

Publication number
BRPI0407611A
BRPI0407611A BRPI0407611-7A BRPI0407611A BRPI0407611A BR PI0407611 A BRPI0407611 A BR PI0407611A BR PI0407611 A BRPI0407611 A BR PI0407611A BR PI0407611 A BRPI0407611 A BR PI0407611A
Authority
BR
Brazil
Prior art keywords
protein
active ingredient
cancer agent
agent
cancer
Prior art date
Application number
BRPI0407611-7A
Other languages
English (en)
Inventor
Hyunkyung Yu
Jang-Seong Kim
Jin-Hyung Ahn
Ho-Jeong Lee
Kwa-Yub Kang
Hyung-Kwon Lim
In-Hwan Lim
Sung Geun Kim
Hak Kyu Joo
Jihyun Lee
Yeup Yoon
Doo-Hong Park
Jung Hwan Park
Original Assignee
Mogam Biotech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotech Res Inst filed Critical Mogam Biotech Res Inst
Publication of BRPI0407611A publication Critical patent/BRPI0407611A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"AGENTE ANTI-CáNCER COMPREENDENDO PROTEINA LK8 COMO UM INGREDIENTE ATIVO". A presente invenção se refere a um agente anti-câncer compreendendo proteina LK8 como um ingrediente ativo. O agente anti-câncer da presente invenção é efetivo para reprimir crescimento e metástase de tumor maligno. Desse modo, o agente pode ser efetivamente usado não somente como repressor de metástase de câncer, mas também como agente terapêutico de tumor malígno primário.
BRPI0407611-7A 2003-02-20 2004-02-20 agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo BRPI0407611A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030010797A KR100595364B1 (ko) 2003-02-20 2003-02-20 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
PCT/KR2004/000357 WO2004073730A1 (en) 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient

Publications (1)

Publication Number Publication Date
BRPI0407611A true BRPI0407611A (pt) 2006-02-14

Family

ID=36116045

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407611-7A BRPI0407611A (pt) 2003-02-20 2004-02-20 agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo

Country Status (9)

Country Link
EP (1) EP1608395A4 (pt)
JP (1) JP2006518342A (pt)
KR (1) KR100595364B1 (pt)
CN (1) CN100546646C (pt)
AU (1) AU2004212856B2 (pt)
BR (1) BRPI0407611A (pt)
CA (1) CA2516172A1 (pt)
RU (1) RU2306147C2 (pt)
WO (1) WO2004073730A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285277B2 (en) 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
KR100681762B1 (ko) * 2004-01-09 2007-02-15 재단법인 목암생명공학연구소 인간 아포리포단백질(ａ) 크링글 ＬＫ68 또는 ＬＫ8유전자를 유효성분으로 함유하는 항암 치료제 및 그를이용한 암 치료방법
CA2571420A1 (en) 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
KR100888022B1 (ko) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
JP5715817B2 (ja) 2007-07-19 2015-05-13 ビオメリューＢｉｏｍｅｒｉｅｕｘ 結腸直腸癌のインビトロ診断のための肝臓脂肪酸結合タンパク質、ｃｅａおよびｃａ１９−９のアッセイのための方法
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2012067427A2 (ko) * 2010-11-16 2012-05-24 재단법인 목암생명공학연구소 Lk8 단백질을 유효성분으로 포함하는 당뇨망막병증 또는 노인성 황반변성의 예방 또는 치료용 약학 조성물
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384929C (en) * 1999-09-15 2006-12-05 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor

Also Published As

Publication number Publication date
WO2004073730A1 (en) 2004-09-02
AU2004212856B2 (en) 2007-07-19
AU2004212856A1 (en) 2004-09-02
JP2006518342A (ja) 2006-08-10
EP1608395A1 (en) 2005-12-28
CN100546646C (zh) 2009-10-07
RU2306147C2 (ru) 2007-09-20
RU2005129273A (ru) 2006-03-10
EP1608395A4 (en) 2007-10-31
CA2516172A1 (en) 2004-09-02
KR20040075270A (ko) 2004-08-27
KR100595364B1 (ko) 2006-07-03
CN1753685A (zh) 2006-03-29

Similar Documents

Publication Publication Date Title
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
SE0101387D0 (sv) Novel compounds
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
UY28441A1 (es) Derivados de quinazolina
EP1423107A4 (en) FATTY ALCOHOL DRUG CONJUGATES
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
GB0112348D0 (en) Compounds
ATE408601T1 (de) Fredericamycin-derivate
EP1819227A4 (en) PHARMACEUTICAL FORMULATIONS OF DECITABIN
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
SE9900961D0 (sv) Novel compounds
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
SE0100158D0 (sv) Novel method and composition for local treatment of Meniere´s disease and tinnitus
GB0121490D0 (en) Ciompounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]